Stock Ratings / Consumer Staples / PETS / forecast

YI (37) RDGT (37) GRDN (71) CVS (61) ⌘ Pro Terminal →

PetMed Express Inc. (PETS) 12-Month Stock Forecast & Price Target Cone

$1.19 +0.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.19

PetMed Express Inc. (PETS) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $25.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PETS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PETS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, PetMed Express Inc. (NASDAQ: PETS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.19 (+0.85% 1D, market cap $25.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 146 tracked Consumer Staples issuers, PETS ranks #145 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PETS compare to YI and RDGT in the Consumer Staples sector?

▼

Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), PETS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -35.0%. By comparison, YI (111 Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M) and RDGT (Ridgetech Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PETS?

▼

Per PETS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001040130), PetMed Express Inc. generated $179.0M in revenue (-21.1% YoY), -$57.3M in net income, and -$33.0M in free cash flow against $88.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.19 (-0.04%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-17.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PETS)Realized 20D OHLCV Swing Band: ±7.8%

Deterministic 5-Pillar Attribution (19/100 Composite)

🔍 WHY PETS SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (32% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 28.1% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.26-8.7% Next Q

Q2 (-2Q)

Grade E$1.15+0.9% Next Q

Q3 (-1Q)

Grade E$1.16+2.6% Next Q

Current

Grade E$1.19-12% Hist 90D α

Trajectory: E (27) → E (19)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PETS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PETS currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Consumer Staples with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.47) and Max Pain ($1.25) forces dealer call-delta covering toward $4.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PETS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PETS Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 19%NO 81%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PETS Position Size: $10,000

Shares at $1.19: 8403.4 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.76

$6,387

$-3,613 (-36.1%)

12M Consensus BaseTarget $0.98

$8,235

$-1,765 (-17.6%)

12M Bull Case BreakoutTarget $4.30

$36,134

+$26,134 (+261.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$4	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PETS)

✓Walkthrough of PETS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PETS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.58%▼ DESCENDING CHANNEL

2026-11-02O $1.19H $1.19L $1.18C $1.19VOL 12.5K

RES: $1.49SUP: $1.04SMA50: $1.47SMA200: $2.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PETS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PETS Butterfly Map → + Track PETS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -21.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PETS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PETS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PETS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PETS)

Consumer Staples Rank #145 of 146 ⚔️ YI vs PETS Full Matrix →

1. Head-to-Head Consumer Staples Peer Comparison (PETS vs. YI, RDGT, GRDN, CVS)

Industry: Retail-Drug Stores and Proprietary Stores (5 Tracked Issuers)

Across 146 tracked Consumer Staples securities in the Roarable RQD universe, PetMed Express Inc. (PETS) ranks #145 by composite RQD confidence (19/100, grade E) and #117 by equity capitalization ($25.6M). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with PETS at 19/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PETS ACTIVE PetMed Express Inc.	E	19/100	—	28.1%	-35.0%	+0.85%	$25.6M	Benchmark Subject
YI 111 Inc.	D-	37/100	—	5.8%	-20.5%	-4.36%	$26.2M	/yi-vs-pets →
RDGT Ridgetech Inc.	D-	37/100	—	3.6%	—	-3.32%	$3.0M	/rdgt-vs-pets →
GRDN Guardian Pharmacy Services Inc. (Class A)	B-	71/100	52.1x	20.2%	37.7%	+0.59%	$2.56B	/grdn-vs-pets →
CVS CVS Health Corporation	C-	61/100	65.3x	45.0%	2.6%	-0.09%	$115.53B	/cvs-vs-pets →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001040130

In its most recent audited fiscal period (FY2025, filed 2026-03-31), PetMed Express Inc. (PETS) reported GAAP revenue of $179.0M (-21.1% vs. FY2024 revenue of $227.0M , and -34.7% cumulative change since FY2023) , GAAP net income of -$57.3M, operating cash flow of -$28.4M, and free cash flow of -$33.0M (-8256.7% YoY). On the balance sheet, PETS closed FY2025 with $88.0M in total assets against $0 in total debt (Altman Z-Score: 0.24, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$179.0M	-$57.3M	-$28.4M	-$33.0M	$88.0M	—
FY2024 (FY)	2025-03-31	$227.0M	-$6.3M	$4.7M	-$395.0K	$144.8M	—
FY2023 (FY)	2024-03-31	$274.1M	-$7.5M	$4.3M	$4.3M	—	—

3. PETS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PETS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PETS compare to YI and RDGT in the Consumer Staples sector?

What are the biggest fundamental strengths and SEC risk factors for PETS?

Where is PETS trading relative to its 50-day, 200-day, and 52-week technical levels?

PETS last traded at $1.19 (+0.85% on volume of 42,359 shares), positioning the stock -19.05% below its 50-day simple moving average ($1.47) and -43.33% below its 200-day simple moving average ($2.10). Across its 52-week range of $1.15 to $4.10, PETS sits at the 1.4% percentile with a 14-day RSI of 33.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.8% ($1.10 to $1.28).

PETS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PETS's 12-month stock price target?

PetMed Express Inc. (PETS) carries a 12-month consensus base price target of $0.98 (-17.6% from $1.19), with a bull-case target of $4.3 and a bear-case floor of $0.76.

Is PETS stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates PETS E (Strong Sell — SELL) with an RQD Confidence score of 19/100.

Direct Sub-Reports: PETS RQD Cockpit PETS 12M Forecast PETS Earnings & Move PETS Dividends & DRIP PETS Insiders & 13F PETS Whale Options PETS Profit Sankey PETS News & Why

ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PETS — PetMed Express Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:19Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PETS carries an RQD Score of 19 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 5 of 20 (ROIC of -35%; FCF yield of 0%), indicating the business is not currently converting capital into returns or free cash. Whale/13F Flow scores 3 of 20 on institutional accumulation and options positioning, suggesting limited institutional support. Insider Conviction scores 3 of 20 on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 6 of 20, reflecting a Beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 2 of 20, with an Altman Z of 0.24, a Piotroski F of 2/9, and a Debt/Equity of 0.5. For a prospective investor, the upside case rests on any reversal in cash generation, which the rating does not show as currently present. The valuation tradeoff is that a $1.18 share price against a $25.6M market cap sits within a 52-week range of $1.15 to $4.10, and the forensic pillars indicate elevated distress risk. Second-order implications are that weak balance-sheet metrics can constrain strategic flexibility even if operating conditions stabilize.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$179.0M	$-58.7M	$-57.3M	N/A	$-33.0M	$26.9M	N/A
FY 2024	$227.0M	$-1.5M	$-6.3M	N/A	$-0.4M	$50.1M	N/A
FY 2023	$274.1M	$-8.2M	$-7.5M	N/A	$4.3M	N/A	N/A

Per the SEC financials, revenue declined from $274.1M in FY 2023 to $179.0M in FY 2025, while net losses widened to $-57.3M in FY 2025. Per the market data, gross margin is 28.1%, operating margin is -32.8%, and net margin is -32%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.24, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash declined from $50.1M in FY 2024 to $26.9M in FY 2025 alongside negative free cash flow of $-33.0M.

Recent Catalysts & News Wire Analysis

Per the recent news feed, a live webcast covering PetMeds results is scheduled for Nov. 10 at 4:30 p.m. ET, which is the most concrete near-term event in the source data. A Form 4 filing by Jeffrey Allen Willard (Director, CEO and President) dated 28 September is referenced. One headline reports the stock gaining 4.35 percent on Nasdaq alongside a Morgan Stanley target of USD 1.40, flagged as a catalyst. Another headline references traders eyeing $1.13 support with an IV spike, a technical item. Several feed items are generic market-wire entries with no substantive content. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links or proprietary signals.

Open Questions

What drove the revenue decline from $274.1M in FY 2023 to $179.0M in FY 2025, and is it expected to continue?
What are the drivers of the FY 2025 net loss of $-57.3M, and is there a path to positive operating income?
What is the composition of the $26.9M cash balance relative to the FY 2025 free cash flow burn of $-33.0M?
What are the terms and amount of debt, given that the debt field is reported as N/A for all periods?
What do the forthcoming Nov. 10 results disclose about trajectory, and how does the Form 4 activity relate to them?

PETS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PetMed Express Inc. (PETS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PETS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 5h ago

PetMed Express, Inc. (PETS) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 8h ago

A live webcast will cover PetMeds' results on Nov. 10 at 4:30 p.m. ET

Stock Titan report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 11h ago

Pet Service Holding NV Announces the Availability of the 2026 Half-Year Financial Report

Yahoo Finance report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 14h ago

Form 4 PetMed Express Inc: Jeffrey Allen Willard (Director, CEO and President) For: 28 September

Investing.com UK report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ad-hoc-news.de • 17h ago

PetMed Express stock gains 4.35 percent on Nasdaq. Morgan Stanley holds USD 1.40 target

ad-hoc-news.de report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 20h ago

PetMed Express (PETS) Ticks Higher to $1.19 as Traders Eye $1.13 Support - IV Spike

https://www.dars.gov.et/ report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 23h ago

PETS Q3 2026 Earnings: Reported Loss of $0.28 Per Share Falls Well Short of Consensus

https://www.dars.gov.et/ report covering PetMed Express Inc. (PETS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 6d ago

PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026

DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PETS Bull vs. Bear Conversation Board — What's Your Call at $1.19?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PETS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.04 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PETS (E • RQD 19/100) a Buy at $1.18?

Welcome to the PETS (PetMed Express Inc.) Roar Pit. Current RQD Composite is 19/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Retail-Drug Stores and Proprietary Stores. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.97 (-17.8%)

Spot @ $1.18

Pump the brakes on PETS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PETS, but look at what you are paying: current EV/EBITDA multiples with 28.1% gross margins. Unless PetMed Express Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.43 (+21.2%)

Spot @ $1.18

PETS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PETS, the market is fixating on short-term headline noise in Retail-Drug Stores and Proprietary Stores and ignoring the balance sheet and cash flow trajectory. At $1.18 (52-wk range $1.15 - $4.10), any beat on forward guidance forces shorts and underweight funds to chase.